Nonsteroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 10, 2004, Pages

  Asano, Tracey K ^a   McLeod, Robin S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOMA; CARCINOMA; CLINICAL TRIAL; COLON POLYPOSIS; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; HUMAN; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA; COLORECTAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION;

EID: 3843096220     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004079.pub2     Document Type: Article

References (56)

1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeowyn-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck, GJ, Bond JH, Byers T Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F vanStok RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. x-wiley/crsRef/18056383
2. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-yr results of the APACC Trial. Gastroeneterology 2003;125:328-336. x-wiley/crsRef/18056385
3. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-24. x-wiley/crsRef/18056387
4. The Steering Committee of the Physicians' Health Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988;318:262-64. x-wiley/crsRef/18056388
5. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus JA. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6. x-wiley/crsRef/18056390
6. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman GE, Hubbard W, Offerhaus JA, Hamilton SR. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9. x-wiley/crsRef/18056392
7. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-39. x-wiley/crsRef/18056394
8. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7. x-wiley/crsRef/18056396
9. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. x-wiley/crsRef/18056398
10. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52. x-wiley/crsRef/18056400
11. Nugent KP, Famer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial polyposis. Br J Surg 1993;80:1618-19. x-wiley/crsRef/18056402
12. Benamouzig R, Yoon H, Little J, Martin A, Douturier D, Deyra J, Coste T, Chaussade S. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 2001;10:327-35. x-wiley/crsRef/18056404
13. Burns J, Chapman PD, Bertario L, Bishop DT, Bulow S, Cummings J, Mathers J, Phillips R, Vasen H. The protocol for a European double-blind trial of aspirin and resistant starch in Familial Adenomatous Polyposis: The CAPP Study. E J Cancer 1995;31A:1385-86. x-wiley/crsRef/18056406
14. Burns J, Chapman PD, Mathers J, Bishop DT, Lynch H. CAPP2: An international controlled trial of aspirin and resistant starch in carriers of HNPCC. J Med Genet 1997;34[Supplement 1]:S53. x-wiley/crsRef/18056408
15. Phase II Randomized study of celecoxib with or without eflornithine for the prevention of colorectal cancer in participants with familial adenomatous polyposis of the colorectum (Summary last modified 04/2002). BioMed Central, [Protocol available online. Accessed Nov 2002 at http://www.cancer.gov/search/clinical trials]. x-wiley/crsRef/18056410
16. PhaseIIB randomized study of eflornithine (DFMO) and sulindac in the prevention of colorectal carcinoma in patients with previously resected colorectal adenoma (Summary last modified 07/2002). BioMed Central, [Protocol available online. Accessed Nov 2002 at http://www.cancer.gov/search/clinical trials]. x-wiley/crsRef/18056412
17. Randomized study of aspirin and/or folic acid as prevention of recurrent colorectal adenomas in patients who have had colorectal adenomas in patients who have had colorectal adenomas removed (Summary last modified 04/2002). BioMed Central, [Protocol available online. (Accessed March 2003 at http://www.controlled-trials.com)]. x-wiley/crsRef/18056414
18. Anonymous. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials 1998;19(1):61-109. x-wiley/crsRef/18056416
19. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. B-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;91:2102-6. x-wiley/crsRef/18056418
20. American Cancer Society, Inc Cancer Facts & Figures. [available on-line: accessed on Feb. 2003, http://www.cancer.org]. American Cancer Society. American Cancer Society, Inc, 2003.
21. Arber N. Do NSAIDs prevent colorectal cancer? Canadian Journal of Gastroenterology 2000;14:299-307.
22. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658-62.
23. Canadian Cancer Society Canadian Cancer Statistics. [available on-line: Accessed Feb. 2003, http://www.cancer.ca]. Canadian Cancer Society. Canadian Cancer Society, 2002.
24. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. http://www.cochrane.dk/cochrane/handbook/handbook.htm (accessed 12 May 2003). Clarke M, Oxman AD, editors. John Wiley and Sons, 2003.
25. Cruz-Correa M, Hylinda LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 2002;122:641-45.
26. National Cancer Institute Common toxicity criteria. [available on-line: accessed August 13. 2002, at http//ctep.cancer.gov/reporting.ctc.html]. National Cancer Institute. National Cancer Institute, 1998.
27. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Seminars in Oncology 1999;26:499-504.
28. Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine 2001;345:433-42.
29. Gupta RA, Dubois RN. Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Annals of the New York Academy of Sciences 2000;910:196-206.
30. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348(9040):1472-7.
31. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;86:1731-43.
32. Hill MJ, Morson BC, Bussey HJR. Aetiology of adenoma - carcinoma sequence in large bowel. The Lancet 1978;1:245-247.
33. Keller JJ, Offerhaus GJA, Drillenburg P, Caspers E, Musler A, Ristimaki A, et al. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clinical Cancer Research 2001;7:4000-7.
34. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988;62:645-51.
35. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
36. Ladabaum U, Chopra CL, Huanga G, Scheiman JM, Chernew ME, A. M. F. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 2001;135:769-81.
37. Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for fecal occult blood. New England Journal of Medicine 1993;328(19):1365-71.
38. The Steering Committee of the Physicians' Health Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988;318:262-4.
39. anonymous. Morbidity and Mortality Weekly Report [Trends in screening for colorectal cancer - United States, 1997 and 1999]. 2001;50:162-6.
40. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-59.
41. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. Journal of the National Cancer Institute 1992;84:1572-5.
42. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7.
43. Paganini-Hill A. Aspiring and the prevention of colorectal cancer: A review of the evidence. Seminars in Surgical Oncology 1994;10:158-164.
44. Seow-Choen F, Pappalardo G, Maiani G, et al. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surgery 1996;83:1763-6.
45. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology 1987;93:1009-13.
46. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: Post-trial follow-up datafrom the Physicians' Health Study. Ann Intern Med 1998;128(9):713-20.
47. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysis. Gastroenterology 2002;122:78-84.
48. Theisen C. Chemoprevention: What's in a name? Journal of the National Cancer Institute 2001;93:743.
49. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac. Lancet 1994;343:180.
50. Trends in screening for colorectal cancer - United States, 1997 and 1999. Trends in screening for colorectal cancer - United States, 1997 and 1999. Morbidity and Mortality Weekly Report 2001;50:162-66.
51. Turner D, Berkel HJ. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Canadian Medical Association Journal 1993;149:595-602.
52. In: http://www.ctu.mrc.ac. A multi-centre double blind randomised controlled trial of Aspirin and / or Folate supplementation for the prevention of recurrent colorectal adenomas. 2002.
53. anonymous. US Preventive Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale. Ann Intern Med 2002;136:161-172.
54. Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiology, Biomarkers and Prevention 1997;6:749-53.
55. Vernon SW. Participation in colorectal cancer screening: A review. Journal of the National Cancer Institute 1997;89(19):1406-22.
56. Winawer SJ, Zauber AG, Ho MN. Prevention of colorectal cancer by colonoscopic polypectomy. The New England Journal of Medicine 1993;329(27):1977-81.